Table 3.
Overall survival: multivariate proportional hazard analysis
| Variable | Hazard ratio | 95% CI | P value |
|---|---|---|---|
| Treatment: decitabine vs TC |
0.799 |
(0.653–0.978) |
0.0296 |
| Sex: male vs female |
1.125 |
(0.912–1.388) |
0.2703 |
| Age group |
|
|
|
| 70–74 vs <70 years |
1.311 |
(1.004–1.711) |
0.0468 |
| ≥75 vs <70 years |
1.560 |
(1.198–2.032) |
0.0010 |
| Baseline cytogenetic risk: intermediate vs poor |
0.699 |
(0.565–0.865) |
0.0010 |
| Type of AML: de novo vs secondary |
1.110 |
(0.893–1.380) |
0.3452 |
| Baseline ECOG PS: 0 or 1 vs 2 |
0.771 |
(0.607–0.978) |
0.0321 |
| Geographic region [8] |
|
|
|
| Eastern Europe vs North America/Australia |
1.118 |
(0.849–1.473) |
0.4263 |
| Western Europe vs North America/Australia |
0.727 |
(0.523–1.010) |
0.0572 |
| Asia vs North America/Australia |
1.047 |
(0.728–1.505) |
0.8052 |
| Western Europe vs Eastern Europe |
0.650 |
(0.482–0.877) |
0.0048 |
| Western Europe vs Asia |
0.694 |
(0.472–1.021) |
0.0637 |
| Baseline bone marrow blast: >50% vs ≤50% |
1.355 |
(1.099–1.672) |
0.0045 |
| Baseline platelets (109/L)a |
0.775 |
(0.663–0.907) |
0.0015 |
| Baseline WBC (109/L)b | 1.256 | (1.045–1.509) | 0.0151 |
AML, acute myeloid leukemia; CI, confidence interval; ECOG PS, Eastern Cooperative Oncology Group Performance Status; TC, patient's choice of treatment with physician's advice; WBC, white blood cell counts.
aHazard ratio less than 1 indicates lower risk associated with each additional 100 × 109/L in baseline platelet counts.
bHazard ratio greater than 1 indicates higher risk associated with each additional 25 × 109/L in baseline WBC counts.